Research Summary
Cannabis on U.S. Roads: By the Numbers
Of individuals injured or killed in U.S. crashes (2019–2021), 25% tested positive for cannabis — outpacing alcohol at 23%.[3]
Weekend nighttime drivers testing positive for cannabis increased 48% between 2007 and 2013–2014 (8.6% to 12.6%).[1]
14 states prosecute cannabis DUI for any detectable amount of THC or its metabolites — regardless of actual impairment at the time of driving.[3]
Why Cannabis DUI Is Scientifically Different From Drunk Driving
To understand why cannabis impaired driving laws are so fragmented, you first need to understand how THC behaves in the human body — and why it cannot be regulated the same way alcohol is.
Alcohol: Predictable, Linear, Testable
Alcohol is water-soluble and distributes evenly throughout the body's water compartments. When you drink, your blood alcohol concentration (BAC) rises in a predictable, dose-dependent relationship to the amount consumed and your body weight.[4] As your liver processes alcohol at a reliable rate, BAC falls and impairment reliably decreases. This linear metabolic relationship is why a universal 0.08% per se limit is scientifically defensible: at that concentration, driving performance is measurably degraded across the general population.
THC: Lipophilic, Non-Linear, and Deceptive
THC — the primary psychoactive compound in cannabis — is highly lipophilic, meaning it aggressively binds to fat cells rather than water.[4] When cannabis is inhaled, THC floods into the bloodstream immediately, causing a massive spike in blood plasma concentration. But within minutes, it rapidly redistributes from the blood into fat and brain tissue, causing blood THC levels to plummet — even as the driver remains cognitively impaired.[1]
The liver then converts active Delta-9-THC into two metabolites. First, 11-hydroxy-THC — a potent, psychoactive compound that continues to cause impairment. Then, 11-Nor-9-carboxy-Δ9-THC (THC-COOH) — an entirely inactive metabolite that produces no psychoactive effects but remains stored in fat cells and slowly leaches back into the bloodstream for days or weeks.[1]
The Core Legal Problem
Because inactive THC-COOH metabolites linger in a chronic user's system for weeks after the psychoactive effects have completely dissipated, a blood test cannot reliably distinguish between a driver who is actively impaired and one who consumed cannabis days ago and is currently sober. This poor correlation between blood THC concentration and actual impairment makes a universal per se threshold scientifically difficult to defend — and is why state laws are so inconsistent.[4]
How Cannabis Actually Impairs Driving
The inability to establish a clean numerical threshold does not mean cannabis is harmless behind the wheel. Controlled clinical studies consistently document measurable impairment across the skills required for safe driving:[8]
- Lane control: Drivers under the influence of THC exhibit increased Standard Deviation of Lateral Position (SDLP) — the scientific measure of lane weaving. They are more likely to drift, overcorrect, and make unintended lane departures.
- Divided attention: Operating a vehicle is inherently a multi-task environment. Cannabis users show dramatic performance collapses when cognitive load increases — navigating an intersection while monitoring surrounding traffic, for example.
- Reaction time: Compensatory behaviors like following distance and speed reductions are largely ineffective when unexpected hazards arise at higher speeds.
- Edibles are worse: Oral cannabis produces more noticeable and longer-lasting impairment than inhaled cannabis because of the delayed digestive onset, which can catch drivers off guard hours after consumption.
Critically, researchers have found no evidence that medical cannabis patients or heavy recreational users develop sufficient tolerance to negate driving deficits from THC. As one peer-reviewed synthesis of the evidence concluded: "cannabis is cannabis" — it produces impairments regardless of the user's intent or tolerance level.[8]
The Patchwork of State Laws: Three Frameworks
Without a scientifically validated universal impairment threshold, U.S. states have enacted three distinct legal frameworks for cannabis-impaired driving. Understanding which framework your state uses determines your legal exposure.[3]
14 states
Zero Tolerance
Definition: Prohibits driving with any detectable amount of THC or its metabolites (including inactive ones) in bodily fluids. The prosecution does not need to prove actual impairment — only the chemical presence of the substance.
Jurisdictions: 10 states prohibit THC or any metabolite; 4 states prohibit THC but do not restrict inactive metabolites.
Key risk: A chronic cannabis user who has not consumed in two weeks may still test positive and be convicted of a DUI under this framework. [↗]
6 states
Non-Zero Per Se Limits
Definition: Establishes a specific quantitative blood-THC threshold. Testing at or above that limit triggers automatic legal intoxication — regardless of observable driving behavior or actual cognitive state.
Jurisdictions: Illinois, Ohio, Pennsylvania, Montana, Nevada, and Washington state have per se limits ranging from 1 to 5 ng/mL of active Delta-9-THC.
Key risk: Because blood THC drops rapidly after smoking while impairment persists, a driver may fail a test taken hours later while having been impaired at the time of driving — or vice versa. [↗]
Majority of states
Permissible Inference / Impairment-Based
Definition: Does not use a numerical chemical threshold. Instead, prosecution relies on officer observation, field sobriety test performance, and Drug Recognition Expert (DRE) testimony to establish impairment. Some states allow a judge or jury to "infer" impairment from a high blood-THC result, but the defense may rebut that inference.
Jurisdictions: Colorado uses a 5 ng/mL "permissible inference" threshold — not an automatic conviction. Most remaining states rely entirely on officer testimony and behavioral evidence.
Key risk: While harder to prosecute, these states still support criminal DUI convictions. DRE testimony about physical symptoms of cannabis impairment is admissible evidence in all 50 states. [↗]
Pennsylvania: The Strictest Standard — and the Medical Card Trap
Pennsylvania serves as the clearest illustration of how zero-tolerance cannabis DUI laws operate in practice — and why a medical marijuana card offers drivers no legal protection.
Under 75 Pa. C.S. § 3802(d), it is unlawful for any person to drive, operate, or be in actual physical control of a vehicle if there is "any amount" of a Schedule I controlled substance present in the driver's blood.[5] Because marijuana remains federally classified as Schedule I, this statute applies to every cannabis user regardless of state medical authorization.
Critical: The Metabolite Trap
Pennsylvania's statute is exhaustive: Section 3802(d)(1)(i) prohibits the presence of the Schedule I substance itself; Section 3802(d)(1)(iii) explicitly prohibits the metabolite of that substance.[5]
This means a driver who consumed cannabis three weeks prior and is currently completely sober will be convicted of a highest-tier DUI if their blood contains the inactive THC-COOH metabolite — a compound that produces no psychoactive effects whatsoever. A Pennsylvania cannabis DUI carries the same mandatory minimums, license suspensions (up to 18 months), and permanent criminal record as the highest rate of alcohol intoxication.
Medical Marijuana Patients Are Not Exempt
Pennsylvania operates one of the country's largest medical marijuana programs, yet registered patients receive zero statutory protection from DUI prosecution. Pennsylvania appellate courts have consistently upheld these convictions. In Commonwealth v. Michael David Smith, the Superior Court rejected equal protection and due process challenges, ruling that because marijuana remains a Schedule I substance, the state has a compelling interest in strict liability enforcement regardless of the patient's legal authorization to possess the drug.[5] The same conclusion was reached in the Dabney case, which rejected arguments that medical cannabis should not be treated as a Schedule I substance for DUI purposes.
Proposed legislation (House Bill 983) seeks to change this by removing per se DUI penalties for legal medical cannabis use while maintaining criminal liability for drivers who are actually physically impaired. As of June 2026, that bill has not been enacted into law.
The Philadelphia DA's Internal Exception
Recognizing the pharmacokinetic reality that chronic cannabis consumers retain elevated baseline THC levels, the Philadelphia District Attorney's Office published a formal internal policy that deviates significantly from the strict "any amount" state law.[6]
Philadelphia DA Office — Internal Cannabis DUI Policy (November 2021)
5 ng/mL or more (Active Delta-9-THC)
DA Action
ADA may assume driver was impaired and proceed with prosecution.
Inactive metabolite only (THC-COOH)
DA Action
ADAs are strictly barred from prosecution. No charge filed.
4 ng/mL or less (Active THC) + BAC 0.08%+
DA Action
Must charge under the alcohol statute only, not cannabis DUI.
4 ng/mL or less (Active THC) + BAC 0.07% or less
DA Action
Prosecution requires credible evidence of unsafe driving or officer observation of actual impairment before proceeding.
Source: Philadelphia District Attorney's Office internal policy.[6] Note: This is prosecutorial discretion, not a statutory amendment. Philadelphia police may still arrest under state law; the policy governs charging decisions only.
How Police Detect Cannabis Impairment: The Drug Recognition Expert Protocol
Because no reliable roadside breathalyzer for cannabis exists, law enforcement agencies depend on a highly structured behavioral and physiological assessment protocol when they suspect drug-impaired driving. This is the Drug Evaluation and Classification (DEC) Program, which certifies specialized officers as Drug Recognition Experts (DREs) under coordination by the International Association of Chiefs of Police (IACP) with NHTSA support.[7]
If you are arrested for suspected cannabis DUI, a DRE may conduct a standardized 12-step physical and cognitive evaluation. The DRE's objective is to determine: (1) whether you are actually impaired; (2) whether impairment is drug-related or from injury or medical condition; and (3) which specific drug category or combination is the likely cause.[7]
The 12-Step DRE Evaluation (Condensed)
- 1Breath Alcohol Test: Establishes whether BAC alone explains observed impairment. If not, a DRE is called.
- 2Officer Interview: DRE reviews BAC results and officer observations of your driving and field sobriety tests.
- 3Preliminary Exam & First Pulse: Rules out head trauma or medical emergencies; records baseline heart rate.
- 4Eye Examinations: Tests for Horizontal Gaze Nystagmus (HGN), Vertical Gaze Nystagmus (VGN), and Lack of Convergence (LOC).
- 5Divided Attention Tests: Walk and Turn, One Leg Stand, Finger to Nose, Modified Romberg Balance.
- 6Vital Signs & Second Pulse: Blood pressure and body temperature measured; second heart rate recorded.
- 7Dark Room Pupil Exam: Pupil size measured under three lighting conditions with a pupilometer.
- 8Muscle Tone Exam: Arms physically palpated — excessive rigidity or flaccidity indicates different drug categories.
- 9Injection Sites & Third Pulse: Examines for puncture wounds; completes the vital sign matrix.
- 10Subject Statements: After Miranda rights are confirmed, subject is questioned about drug use.
- 11DRE Opinion: DRE synthesizes all data to form a sworn expert opinion on impairment and drug category.
- 12Toxicological Sample: Blood, urine, or oral fluid collected for laboratory confirmation.
What Cannabis Looks Like to a DRE: The Symptom Matrix
Each drug category produces a distinct physiological profile. The IACP's official symptomatology matrix maps observable symptoms to drug classes, allowing a DRE to distinguish cannabis impairment from alcohol intoxication, stimulant use, or other conditions. For cannabis specifically, the clinical signature is highly distinctive:[11]
| Clinical Indicator | Expected Finding Under Cannabis Influence |
|---|---|
| Horizontal Gaze Nystagmus (HGN) | None — cannabis does not cause involuntary eye jerking when tracking horizontally. Absence of HGN is itself a distinguishing marker. |
| Vertical Gaze Nystagmus (VGN) | None — cannabis does not produce vertical nystagmus. |
| Lack of Convergence (LOC) | Present — the subject cannot cross their eyes to focus on a stimulus moving toward the nose. One of the primary clinical indicators. |
| Pupil Size (room light) | Dilated — pupils will typically measure larger than the normal 2.5–5.0mm range. |
| Pupillary Reaction to Light | Normal — pupils still constrict when exposed to direct light, distinguishing cannabis from CNS depressants. |
| Pulse Rate | Elevated — heart rate exceeds the normal 60–90 BPM resting range. One of the primary clinical indicators. |
| Blood Pressure | Elevated — typically presents above the normal 120–140 mmHg systolic range. |
| Body Temperature | Normal — unlike PCP or stimulants, cannabis does not significantly alter core body temperature from the 98.6°F baseline. |
| Muscle Tone | Normal — muscles will not present as abnormally rigid (as with stimulants) or flaccid (as with narcotics). |
| Behavioral Indicators | Bloodshot/reddened conjunctiva ("red eyes"), eyelid tremors, relaxed inhibitions, disorientation, thick or slurred speech, marijuana odor, and visible cannabis debris in the oral cavity. |
Source: IACP/NHTSA DRE Symptomatology Matrix.[11] Highlighted rows are primary clinical indicators a DRE will specifically emphasize in court testimony.
The combination of Lack of Convergence, elevated pulse, elevated blood pressure, and dilated pupils — specifically in the absence of Horizontal Gaze Nystagmus — forms the clinical foundation for a DRE's expert opinion that a driver is impaired by cannabis rather than alcohol or another substance. This testimony is admissible in courts across the country under both Frye and Daubert evidentiary standards.
What Drug Tests Actually Find: Detection Windows by Matrix
Once a DRE evaluation establishes probable cause, law enforcement will collect a biological specimen for laboratory analysis using Gas Chromatography-Mass Spectrometry (GC-MS) or Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) — the forensic gold standard for identifying and quantifying drug compounds at extremely low concentrations.[13] The choice of specimen type is the single most critical variable in a cannabis DUI investigation, because each matrix has a radically different detection window and captures different compounds.
| Matrix | What It Detects | Detection Window | Forensic Utility |
|---|---|---|---|
| Blood | Active Delta-9-THC and psychoactive metabolites | Up to 36 hours (occasional users)2–7 days for chronic users | Best indicator of active intoxication. However, the time required to obtain a warrant and transport the suspect to a medical draw site causes severe delays — during which active THC levels drop rapidly. |
| Urine | Inactive THC-COOH metabolite only | 1–5 days (occasional use)5–15 days (regular use)30+ days (heavy, chronic use) | Highly problematic for DUI enforcement. A positive urine test proves only that the driver consumed cannabis at some point in the past month — it cannot establish impairment at the time of driving. In zero-tolerance states, that is still enough for conviction. |
| Oral Fluid (Saliva) | Active parent drug (Delta-9-THC) from oral cavity | 24–48 hours (light users)Up to 72 hours (heavy users) | Rapidly emerging as the preferred roadside method. Collected non-invasively at the traffic stop immediately after the offense. Detects active parent drug rather than inactive metabolites, correlating more closely with the window of actual impairment. Systematic reviews show high specificity for THC detection. |
Sources: NHTSA Marijuana-Impaired Driving Report[4]; CFSRE Laboratory Survey[13]. Detection windows are population averages; individual results vary based on body fat percentage, metabolism, frequency of use, and potency of product consumed.
Can CBD Get You a DUI?
The passage of the 2018 Farm Bill federally legalized hemp-derived CBD products containing less than 0.3% Delta-9-THC, creating a massive consumer market for oils, gummies, capsules, and topicals. For millions of drivers who use CBD for pain relief, anxiety, or sleep — without any intent to get high — a critical question has emerged: can legal CBD use result in a DUI?
The pharmacological answer is no: pure CBD does not bind to the CB1 receptors in the brain in a way that causes euphoria or compromises motor skills, reaction time, or attention. CBD itself is not an impairing substance under any state vehicle code.
The practical and legal answer, however, is that a CBD user can absolutely be arrested, prosecuted, and convicted of a DUI — particularly in zero-tolerance states — for two distinct reasons.
Reason 1: Trace THC That Bioaccumulates
CBD products fall into three categories, and only one of them is reliably free of THC:
CBD Isolate
0% THCPure CBD chemically stripped of all other plant compounds. The lowest-risk option, but only if the manufacturer's third-party testing is accurate and verified.
Broad-Spectrum CBD
Claims 0% THCContains other cannabinoids and terpenes but removes THC. "Claims 0%" is the key phrase: the FDA does not certify label accuracy, and independent lab tests frequently find trace THC in products marketed as THC-free.
Full-Spectrum CBD
Up to 0.3% THCContains the full hemp phytochemical profile including legally permitted trace THC. Daily use of full-spectrum products introduces continuous microscopic THC doses that bioaccumulate in fat tissue. Chronic users can easily surpass blood test cut-off thresholds (e.g., 5 ng/mL) without having consumed any recreational cannabis.
Because THC is highly lipophilic, trace amounts from full-spectrum CBD products are absorbed into fat tissue rather than immediately flushed out. A daily CBD user who switches to a blood or urine test may find accumulated THC concentrations sufficient to trigger a positive result — and in zero-tolerance states like Pennsylvania, Georgia, and Delaware, that positive result is sufficient for a DUI conviction regardless of impairment.[9]
Reason 2: Mislabeled Products Containing Illegal THC Levels
The FDA does not pre-certify the accuracy of CBD product labels. Independent testing has repeatedly found that products marketed as "0.00% THC" or "THC-free" contain measurable, sometimes illegal, THC concentrations. The FDA has issued formal warning letters to numerous CBD companies for exactly this type of mislabeling. If a driver purchases a product in good faith as THC-free and unknowingly ingests illegal THC levels, their defense — that the detected THC came from a mislabeled consumer product — is an affirmative defense that must be litigated in court, not a shield against the initial arrest.
The Gastric Acid Conversion Myth: Debunked
A persistent theory circulating in legal and chemistry circles claimed that CBD could spontaneously convert into psychoactive Delta-9-THC when exposed to the acidic environment of the human stomach — meaning even pure CBD isolate users could unknowingly become intoxicated. This theory originated from in vitro (test tube) studies that observed such conversions in simulated gastric fluid.
Modern in vivo clinical research has definitively debunked this hypothesis. In a controlled study using minipigs (an animal model with gastrointestinal characteristics highly predictive of human biology), subjects were administered large oral doses of synthetic CBD twice daily for five days. Subsequent GC-MS analysis of blood plasma and gastrointestinal tissue found both Delta-9-THC and 11-OH-THC to be completely undetectable.[12]
Scientific Consensus: No In-Vivo Conversion
Orally ingested CBD does not chemically convert to THC inside the human body. Any positive THC test from a CBD user reflects trace THC natively present in the product prior to ingestion — from manufacturing processes or mislabeling — not an internal physiological reaction. This scientific conclusion is now the consensus view in forensic toxicology.[12]
CBD's Own Detection Window
CBD itself shares THC's lipophilic characteristics and accumulates in fat cells with repeated use. The half-life of CBD ranges from 1.4 to 10.9 hours after a single use, but rises to 2–5 days with chronic daily oral consumption. Because complete elimination requires approximately five half-lives, regular oral CBD use means the compound — and any accompanying trace THC from full-spectrum products — can remain detectable in the body for 10 to 25 days after use ceases. Hydration and exercise have negligible effects on accelerating cannabinoid clearance.[9]
Commercial Drivers: The Strictest Standard in the Country
The legal risk of cannabis and CBD use reaches its absolute apex for drivers holding a Commercial Driver's License (CDL). The U.S. Department of Transportation (DOT) enforces zero-tolerance drug testing protocols under 49 CFR Part 40 that apply to commercial truck drivers, airline pilots, transit vehicle operators, railroad engineers, and pipeline personnel.[9]
Federal Law Overrides State Legalization
49 CFR Part 40 does not authorize the use of Schedule I substances for any reason whatsoever. This federal mandate entirely overrides state-level medical marijuana protections and recreational legalization laws. A CDL holder who tests positive for marijuana metabolites — even if they hold a valid state medical card and live in a fully legal state — faces immediate removal from all safety-sensitive duties, suspension of commercial driving privileges, and mandatory completion of a Substance Abuse Professional (SAP) program before return to duty.[9]
CBD Is Not an Accepted Defense Under DOT Rules
The DOT Office of Drug and Alcohol Policy has issued explicit notices warning safety-sensitive employees that CBD use routinely triggers laboratory-confirmed positive marijuana tests due to product mislabeling and THC bioaccumulation. Under 49 CFR Part 40, Subpart G, a Medical Review Officer (MRO) — the independent physician who reviews positive drug test results — is specifically prohibited from accepting CBD product use as a legitimate medical explanation for a positive THC result. If the specimen meets the established cut-off thresholds, the MRO must verify the test as a positive marijuana failure regardless of the employee's CBD claims.[9]
The Supreme Court Case: Trucker Wins RICO Claim Against CBD Manufacturer
The consequences of mislabeled CBD products for commercial drivers gained landmark legal recognition in Medical Marijuana, Inc. v. Horn, decided by the U.S. Supreme Court on April 2, 2025.[10]
Douglas Horn, a professional commercial truck driver, purchased a CBD product branded as "Dixie X" that was explicitly marketed as containing "0.00% THC." After consuming the product, Horn failed a random employer drug screen. Independent laboratory tests confirmed the product contained illegal THC levels far exceeding the federal limit. Horn was fired after refusing to complete a mandated substance abuse program.
Horn filed suit under the Racketeer Influenced and Corrupt Organizations Act (RICO), arguing the manufacturer's false advertising constituted a predicate act of fraud. The Supreme Court, affirming the Second Circuit, held that nothing in RICO's text, structure, or history bars a plaintiff from recovering treble (triple) damages for lost business or property — here, lost wages and a destroyed career — simply because those economic losses were connected to a personal injury (ingesting a mislabeled substance). Horn's case was allowed to proceed.[10]
What This Ruling Means for Drivers
Medical Marijuana, Inc. v. Horn shifts significant financial liability onto CBD manufacturers for mislabeled products that cost drivers their careers. Consumers can now pursue civil RICO claims with treble damages. However, a parallel ruling in Rocchio v. E&B Paving LLC (S.D. Indiana) confirmed that employees cannot force employers to ignore a failed drug test as an ADA accommodation for CBD use — even when the CBD was being used to treat a documented disability. In short: sue the manufacturer, not the employer.[10]
Frequently Asked Questions
Can you get a DUI from weed if you have a medical marijuana card?
In most states that have per se or zero-tolerance cannabis DUI laws — including Pennsylvania — a valid medical marijuana card provides zero legal protection from impaired driving prosecution. Because marijuana remains a Schedule I controlled substance under federal law, courts have consistently upheld that state medical authorization does not override DUI statutes. Pennsylvania's Superior Court confirmed this in Commonwealth v. Smith and the Dabney case. In impairment-based states with no numerical threshold, having a card does not prevent prosecution if an officer establishes behavioral evidence of impairment.
How long after smoking weed can you legally drive?
There is no established safe waiting period with the scientific precision of alcohol's known metabolic rate. Active THC blood concentrations spike immediately upon inhalation, then fall rapidly as the drug redistributes into fat and brain tissue — yet cognitive impairment can persist for hours after blood levels drop. Most toxicologists advise waiting at least 4–6 hours after smoking and significantly longer (potentially 6–8 hours or more) after consuming edibles, which have delayed onset and prolonged effects. For chronic daily users in zero-tolerance states, even extended abstinence may not eliminate detectable metabolites.
Can CBD get you a DUI?
Pure CBD does not impair driving. However, in zero-tolerance states, even non-impairing trace THC from bioaccumulated full-spectrum CBD can satisfy the statutory requirement for a DUI conviction. In per se limit states, bioaccumulated THC that reaches the blood threshold (e.g., 5 ng/mL) is legally sufficient for conviction regardless of cognitive state. And in all states, mislabeled products containing illegal THC levels create direct impairment risk. CBD users who are arrested cannot simply claim CBD use as a defense to the initial charge — that is an affirmative defense requiring courtroom litigation.
Do police have a breathalyzer for weed?
No widely deployed, scientifically validated roadside breathalyzer for cannabis exists as of June 2026. Unlike alcohol, THC does not distribute in breath in a way that reliably correlates with blood concentration or impairment. Law enforcement currently relies on Standardized Field Sobriety Tests (SFSTs), the 12-step Drug Recognition Expert (DRE) protocol, and laboratory analysis of blood or oral fluid samples. Oral fluid (saliva) swabs are the most promising emerging technology and are already in use in some jurisdictions — they detect active parent-drug THC and can be collected non-invasively at the traffic stop.
Can you get a DUI from weed in a state where cannabis is legal?
Yes, without exception. Recreational legalization does not decriminalize impaired driving. Every state that has legalized recreational cannabis has simultaneously retained or strengthened its impaired driving statute. The distinction is between lawful possession and consumption of cannabis versus operating a motor vehicle while impaired by it — the same principle that applies to alcohol. Legal states typically fall into either a per se limit category or an impairment-based enforcement model.
What happens if you fail a drug test for cannabis as a commercial driver?
Under DOT's 49 CFR Part 40, a verified positive marijuana test triggers immediate removal from all safety-sensitive duties, suspension of CDL privileges, mandatory reporting to the federal Drug and Alcohol Clearinghouse (FMCSA), and enrollment in a Substance Abuse Professional (SAP) program. Return to safety-sensitive duties requires completion of the SAP evaluation, any recommended treatment, a follow-up return-to-duty test, and continued follow-up testing for up to 5 years. CBD use is not an accepted medical explanation under federal regulations — the MRO must verify the test as a positive failure regardless.
What is a Drug Recognition Expert (DRE) and can I refuse the evaluation?
A Drug Recognition Expert is a specially trained law enforcement officer certified to conduct a 12-step physiological and behavioral evaluation of suspected drug-impaired drivers. In states where implied consent laws apply broadly (such as Pennsylvania, where bicycles and vehicles are both covered), refusing a chemical test triggers an automatic administrative license suspension separate from the criminal DUI charge. The DRE evaluation itself — distinct from the chemical test — generally cannot be refused in the same way, and refusal can be documented as evidence of consciousness of guilt.
Legal Disclaimer
This content is provided for informational and educational research purposes only. It does not constitute legal advice and does not create an attorney-client relationship. Cannabis laws, medical marijuana regulations, and DOT drug testing protocols are subject to change; verify current statutes with your state's official code or consult a qualified attorney in your jurisdiction before taking any action. Federal rescheduling proceedings currently underway may alter the legal landscape described in this article.
Primary Source Directory
- NHTSA — Drug-Impaired Driving: National Highway Traffic Safety Administration. Documents the 48% increase in cannabis-positive weekend nighttime drivers (2007–2014) from the National Roadside Survey.
- NCSL — Drugged Driving / Marijuana-Impaired Driving: National Conference of State Legislatures. Overview of state DUI frameworks and the decline in alcohol-positive drivers concurrent with cannabis rise.
- GHSA — Drug-Impaired Driving (Governors Highway Safety Association): Primary source for the three legal framework taxonomy (zero tolerance, per se limits, impairment-based), state counts, and the 2019–2021 trauma center data (cannabis at 25% vs. alcohol at 23%).
- NHTSA — Marijuana-Impaired Driving: A Report to Congress (2017): Mandated by Section 4008 of the FAST Act. Comprehensive federal analysis of THC pharmacokinetics, the alcohol vs. THC metabolic contrast, and the scientific basis for the per se threshold problem.
- 75 Pa. C.S. § 3802 — Pennsylvania Vehicle Code (Driving Under the Influence): Pennsylvania General Assembly. The statutory basis for Pennsylvania's "any amount" cannabis DUI law, including the metabolite prohibition in § 3802(d)(1)(iii).
- Philadelphia District Attorney's Office — Internal Cannabis DUI Policy (November 2021): Formal internal prosecution policy establishing the 5 ng/mL active THC threshold and prohibiting prosecution based on inactive metabolite alone.
- IACP — 12-Step DRE Process (International Association of Chiefs of Police): The official IACP documentation of the Drug Evaluation and Classification (DEC) Program's standardized 12-step evaluation protocol.
- Fischer B. et al. — "Cannabis, Impaired Driving, and Road Safety" (PMC8416748): Peer-reviewed synthesis published via PubMed Central. Source for the "cannabis is cannabis" conclusion regarding tolerance and the SDLP (lane deviation) research findings.
- U.S. Department of Transportation — DOT CBD Notice (ODAPC): Official DOT Office of Drug and Alcohol Policy and Compliance notice regarding CBD risks for safety-sensitive employees, the prohibition on MROs accepting CBD as an explanation for positive tests, and the status of marijuana under 49 CFR Part 40.
- Medical Marijuana, Inc. v. Horn, No. 23-365 (U.S. Supreme Court, April 2, 2025): Supreme Court opinion affirming that civil RICO plaintiffs may recover treble damages for lost wages and career destruction caused by mislabeled CBD products, even when those economic losses derive from a personal-injury antecedent.
- Alabama DRE Symptomatology Matrix (2023) / IACP DRE Matrix: Official Drug Recognition Expert symptomatology chart documenting the clinical indicators for cannabis and each other drug category. Source for the HGN/LOC/pupil/pulse findings.
- Crockett J. et al. — "Cannabidiol Does Not Convert to Δ9-Tetrahydrocannabinol in an In Vivo Animal Model" (PMC5744690): In vivo minipig study published via PubMed Central definitively debunking the gastric acid CBD-to-THC conversion hypothesis.
- Huestis M.A. et al. — "Recommendations for Toxicological Investigation of Drug-Impaired Driving and Motor Vehicle Fatalities" (PMC8272528): Center for Forensic Science Research and Education (CFSRE) survey of 65 forensic laboratories documenting testing matrix preferences and analytical methodologies. Published via PubMed Central.
- NHTSA — Preliminary Training for the Drug Evaluation and Classification Program (2023): Official NHTSA participant manual for DRE preliminary training. Source for the 12-step protocol structure and the three-question determination objective.